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Abstract
Background: Retinoids have been studied extensively for their potential as therapeutic and chemopreventive agents for a
variety of cancers, including nonmelanoma skin cancer (NMSC). Despite their use for many years, the mechanism of action of
retinoids in the prevention of NMSC is still unclear. In this study we have attempted to understand the chemopreventive
mechanism of all-trans retinoic acid (ATRA), a primary biologically active retinoid, in order to more efficiently utilize retinoids
in the clinic.
Results: We have used the 2-stage dimethylbenzanthracene (DMBA)/12-O-tetradecanoylphorbol-13-acetate (TPA) mouse skin
carcinogenesis model to investigate the chemopreventive effects of ATRA. We have compared the gene expression profiles of
control skin to skin subjected to the 2-stage protocol, with or without ATRA, using Affymetrix 430 2.0 DNA microarrays.
Approximately 49% of the genes showing altered expression with TPA treatment are conversely affected when ATRA is co-
administered. The activity of these genes, which we refer to as 'counter-regulated', may contribute to chemoprevention by
ATRA. The counter-regulated genes have been clustered into functional categories and bioinformatic analysis has identified the
B-Raf/Mek/Erk branch of the MAP kinase pathway as one containing several genes whose upregulation by TPA is blocked by
ATRA. We also show that ATRA blocks signaling through this pathway, as revealed by immunohistochemistry and Western
blotting. Finally, we found that blocking the B-Raf/Mek/Erk pathway with a pharmacological inhibitor, Sorafenib (BAY43-9006),
induces squamous differentiation of existing skin SCCs formed in the 2-stage model.
Conclusion:  These results indicate that ATRA targets the B-Raf/Mek/Erk signaling pathway in the 2-stage mouse skin
carcinogenesis model and this activity coincides with its chemopreventive action. This demonstrates the potential for targeting
the B-Raf/Mek/Erk pathway for chemoprevention and therapy of skin SCC in humans. In addition our DNA microarray results
provide the first expression signature for the chemopreventive effect of ATRA in a mouse skin cancer model. This is a potential
source for novel targets for ATRA and other chemopreventive and therapeutic agents that can eventually be tested in the clinic.
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Background
Nonmelanoma skin cancer (NMSC) is the most common
cancer in the U.S., with over a million new cases of the two
most common forms, squamous cell carcinoma (SCC)
and basal cell carcinoma (BCC), anticipated annually [1].
The more clinically aggressive form is SCC [2], which has
been increasing in incidence since the 1960s at annual
rates from 4% to as much as 10% in recent years.
Advanced-disease- and treatment-related morbidity have
a profound impact on patients' quality of life. Unlike
BCC, which bears a single genetic hallmark of disruption
of the patched-sonic hedgehog signaling pathway, the
genetic alterations leading to SCC appear more complex
and varied, and are poorly understood [3]. Better control
of advanced skin SCC is clearly necessary, and will be
greatly helped by improving our understanding of the
molecular basis for skin carcinogenesis and of the action
of chemopreventive drugs.
The mouse skin model of multi-stage carcinogenesis is
one of the best studied and most informative with regard
to understanding molecular mechanisms and the evolu-
tion of cancer cells [4]. It has proven to be ideal for the
study of events leading to the transition from initiation, to
promotion and then progression to carcinoma. Molecular
analysis of multistage human cancers such as prostate and
colon cancer, have shown a high level of genetic and bio-
logical similarity to mouse skin in the 2-stage model. [5].
The SENCAR (sensitive to carcinogen) mouse strain has
been developed for this assay due to its high susceptibility
to chemical-induced tumor formation, relative to most
other strains of mice tested [4].
Retinoids comprise a class of chemical compounds that
includes active metabolites of vitamin A (retinol), as well
as a diverse array of synthetic derivatives. Retinoids mod-
ulate a several cellular processes, including proliferation,
differentiation, homeostasis, malignant transformation
and apoptosis [6]. Retinoids also act pharmacologically to
restore regulation of differentiation and growth in certain
premalignant and malignant cells in-vitro  and  in-vivo.
Consequently, retinoids are being studied extensively for
their potential as therapeutic and chemopreventive agents
for a variety of cancers including skin SCC [7].
It has been previously shown that all-trans retinoic acid
(ATRA), the primary biologically active retinoid found in
the body, reduced both the number of papillomas and
carcinomas that formed in the 2-stage model [8,9]. A pos-
sible mechanism for this effect is revealed from studies of
the AP-1 transcription factor complex, which is comprised
of heterodimers of jun and fos protein family members.
AP-1 is a positive regulator of cell proliferation and trans-
formation and its activity is stimulated by 12-O-tetrade-
canoylphorbol-13-acetate (TPA) [10]. The promotion
step is likely to involve AP-1 since the oncogenic forms of
c-fos and p21ras have been shown to cooperate in convert-
ing normal keratinocytes to squamous cell carcinomas
[11]. The requirement for AP-1 activation for tumor pro-
motion was subsequently shown using transgenic mice
expressing the c-jun transactivation mutant TAM67, under
the control of the basal cell specific keratin 14 promoter
[12]. As would be predicted from the antagonism between
TPA and retinoids, the nuclear retinoid receptors and AP-
1 can antagonize each other's activity for the regulation of
several genes [13,14]. It has further been shown that the
tumor suppressive effect of ATRA in the 2-stage model is
mediated by blocking AP-1 activity, and not through tran-
scriptional activation of retinoic acid responsive genes per
se [14,15]. Finally, a direct link between between MAPK
signaling and AP-1 activity has been established from
studies in which kinase deficient forms of Erk could
inhibit AP-1 activation by several stimuli [16,17]. These
findings have led to several studies aimed at understand-
ing the mechanism of suppression of MAP kinase signal-
ing and/or AP-1 activity by ATRA [18].
The development of DNA microarray technology provides
a powerful tool for identifying genes expressed in a given
cell type or tissue at a particular time [19]. In this study we
have used this technology to not only determine the effect
of a tumor promoting agent (TPA) on normal tissue, but
also to assess the effects of ATRA, a known suppressor of
TPA-induced tumor promotion, in this setting. We have
identified a set of genes that we have termed 'counter-reg-
ulated' by TPA and ATRA. These are TPA regulated genes
(fold expression change ≥ |1.5| between control and TPA
treated skin), which are expressed in the opposite direc-
tion when TPA is co-administered with ATRA (fold change
≥ |1.5| between skin treated with TPA+ATRA and TPA
alone). Such genes provide an expression signature for the
chemopreventive effect of ATRA in the mouse 2-stage skin
cancer model. A prominent component of this signature
is the B-Raf/Mek/Erk branch of the MAP kinase signaling
pathway.
Results
ATRA reverses many of the gene expression changes 
caused by TPA in mouse skin: microarray-based analysis
Our group and others have shown that ATRA can suppress
tumor promotion by TPA in the 2-stage model, but only
as long as it is being co-administered with TPA [9,20]. If
ATRA treatment is discontinued while TPA treatment is
maintained, the mice showed a linear increase in tumor
multiplicity with time after stopping the last treatment
[20]. This suggests that ATRA may be primarily acting to
suppress promotion by TPA, but has little apparent effect
on initiation.Molecular Cancer 2009, 8:27 http://www.molecular-cancer.com/content/8/1/27
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In order to explore the mechanism of the chemopreven-
tive effect of ATRA at an early step during TPA-induced
tumor promotion, we performed Affymetrix DNA micro-
array analyses for mouse skin subjected to the 2-stage pro-
tocol for 3 weeks, with and without co-administration of
ATRA. We chose the 3 week time point because this pre-
cedes the appearance of tumors but is after the TPA treated
skin exhibits pronounced hyperplasia (Fig. 1); and this
time point proved to be advantageous for identifying
genes regulated by TPA plus retinoid combinations in
mouse skin in a previous study from our laboratory [20].
We reason that at least a portion of important TPA-
Experimental design of microarray analysis Figure 1
Experimental design of microarray analysis. A, Mouse skin was treated twice weekly for 3 weeks with either 200 μl ace-
tone solvent (Control), 1 μg TPA in 200 μl acetone (TPA), 5 μg ATRA in 200 μl acetone (ATRA) or ATRA administration fol-
lowed immediately by TPA (T+A). B, Hematoxylin and eosin stain of adjacent skin samples from mice in the same treatment 
groups used for RNA isolation.
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induced promotion events will have taken place by this
time.
Of the ~45,000 probe sets (representing ~39,000 tran-
scripts and variants from over 34,000 characterized mouse
genes) on the 430 2.0 GeneChip, expression of 3,948 were
altered by TPA, upwards or downwards, relative to
untreated controls (fold changes between treatment
groups ≥ 1.5, with p ≤ 0.05). This group of genes was
divided into clusters as described in Materials and Meth-
ods. The heatmap in figure 2 represents the genes that fall
into each subcluster, with expression patterns produced
by normalized raw scores for the subcluster indicated in
the panels on the right. Amongst the 3,948 total TPA reg-
ulated genes, 49.5% were found to be in the C1A and C2A
subclusters. We are calling these genes 'counter-regulated'
because their direction of expression (increase or
decrease) in TPA + ATRA treated skin compared to TPA
treated skin is opposite to that of TPA treated skin com-
pared to control skin. This data can also be represented
graphically as scatterplots (Fig. S1, additional file 1). We
note that when comparing control skin with TPA + ATRA
skin, the majority of counter-regulated genes lie close the
x = y diagonal, indicating that ATRA can suppress TPA
effects on expression of these genes completely or near
completely (Fig. S1C, additional file 1, see C1A and C2A
subclusters). A subset of the C1A and C2A genes are listed
in Table S1 in additional file 2, sorted according to their
known function in cellular signaling pathways, using the
GeneSifter program. The table lists genes in the major sig-
naling pathways in epithelial cells that have the highest Z-
scores. Z-score is a measure of the significance of over-rep-
resentation for a particular gene list within an ontology
group [21]. We also identified several counter-regulated
genes that were previously determined to be TPA regu-
lated (Table S2, additional file 3). This abrogation of TPA
effect on gene expression by ATRA is consistent with the
findings of numerous investigators who have shown that
TPA activates the AP-1 transcription factor complex, and
that AP-1 activity is inhibited by ATRA through the retin-
oid receptors [10] for review and [14,22].
ATRA suppresses B-Raf/Mek/Erk signaling in early and late 
tumor progression times in the 2-stage skin carcinogenesis 
model
Examination of the above microarray results revealed
altered expression of a disproportionate number of genes
involved in the MAP kinase signaling pathway, in particu-
lar the B-Raf/Mek/Erk pathway (Table S1, additional file
2). We next performed a 2-stage skin carcinogenesis exper-
iment as above, except that in this study the protocol was
carried out for 30 weeks. Tumor counts were recorded
each week and mice were sacrificed at multiple time
points (6 hours, 3, 7, 10, and 30 weeks of treatment), for
subsequent analysis of B-Raf/Mek/Erk pathway signaling.
The reduced tumor multiplicity and increased tumor
latency for mice treated with TPA+ATRA, compared to
mice treated with TPA alone, indicated the potent tumor
suppressive activity of ATRA, in agreement with previous
results (Fig. 3A, compare black line with blue line) [8,9].
However a small number of tumors were observed in the
mice treated with TPA+ATRA. Interestingly, histological
examination of these ATRA resistant tumors revealed a
less differentiated phenotype than for the tumors that
arose in the mice treated with TPA alone (Fig. 3B). These
tumors closely resembled advanced SCC, while the
tumors in the TPA mice were papillary, with a high degree
of keratinization as confirmed by a immunohistochemi-
cal (IHC) staining for cytokeratin 10 (Fig. 3B, lower pan-
els). In order to investigate the effects of ATRA on TPA-
induced activation of the B-Raf/Mek/Erk pathway, we per-
formed IHC staining of paraffin sections from mouse skin
treated with TPA, ATRA, TPA+ATRA, or acetone solvent,
with phosphorylation site-specific antibodies to B-Raf
(phospho-Ser 445), Mek1/2 (phospho-Ser 217/221), and
Erk1/2 (phospho-Thr202/Tyr 204). The 6 h, 3, 7, 10 and
30 week time points were selected for sample isolation in
order to obtain data prior to tumor formation (6 h and 3
weeks), just as tumors are beginning to be detectable (7
weeks), after the majority of mice have tumors (10
weeks), and after tumors had grown substantially (30
weeks). In the TPA treated skin, hyperproliferation was
correlated with increased levels of activated (phosphor-
ylated) B-Raf, Mek1/2, and Erk1/2, as detected by
increased red fluorescence from the Alexa 546-coupled
secondary antibody. Results are shown for a representa-
tive (3 week) time point (Fig. 4A; compare TPA panels to
Control panels for all 3 rows). Skin treated with a single
application of TPA, ATRA or TPA+ATRA showed no nota-
ble changes in staining for any of the phosphoproteins
(data not shown). pB-Raf was expressed predominantly in
the cytoplasm in TPA treated skin at all time points, and
this effect was blocked with co-administration of ATRA
with TPA (Fig. 4A, upper rows and data not shown). We
did not observe any changes in phosphorylation of c-Raf
(RAF1), the other Raf family member present in skin, with
any of the treatments using an antibody to phospho-ser-
ine 338 (Fig. S2, additional file 4).
pMek1/2 levels were increased and expression was local-
ized predominantly to the inner surface of the cell mem-
brane in TPA treated skin (Fig. 4A, middle rows). This
observation is notable since it has been shown that the
translocation of pMek to the cell membrane results in
lowering the threshold for activation of MAP kinase signal
output [23]. As was observed for pB-Raf, the increased lev-
els of pMek1/2 was blocked with co-administration of
ATRA. Staining for pErk1/2 was observed in pairs of scat-
tered nuclei in control skin, with an increase in staining
intensity for TPA treated skin, as would be predictedMolecular Cancer 2009, 8:27 http://www.molecular-cancer.com/content/8/1/27
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Heatmap of identified clusters Figure 2
Heatmap of identified clusters. SENCAR mouse skin was treated with TPA or TPA + ATRA. Expression of genes induced 
≥ 1.5-fold by TPA treatment compared to controls (C1A-C subclusters) and suppressed ≥ 1.5 fold by TPA (C2A-C) are indi-
cated in green-red scale (green = low expression, red = high expression, black = intermediate expression). Expression patterns 
of genes for each subgroup are shown in graphs on the right, in which the raw scores were normalized to a mean value of 0 
and a standard deviation of 1.
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Chemopreventive activity of ATRA in the 2-stage model Figure 3
Chemopreventive activity of ATRA in the 2-stage model. A, Tumor multiplicity for mice in the 2-stage skin carcinogen-
esis experiment. Tumors were counted weekly. Error bars represent +/- SEM for each treatment group (n = 5). B, H&E stain 
of paraffin sections from representative tumors isolated from mice in the TPA alone and TPA+ATRA 30 week treatment 
groups. Magnification = 200×. C, IHC staining of serial sections from the same tumors with an antibody to cytokeratin 10 fol-
lowed by an Alexa-488-labeled secondary antibody and counterstaining with DAPI. Magnification = 600×.
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ATRA suppresses TPA induced phosphorylation of B-Raf, Mek1/2, and Erk1/2 Figure 4
ATRA suppresses TPA induced phosphorylation of B-Raf, Mek1/2, and Erk1/2. A. IHC staining of 3 week treated 
skin. Paraffin sections of mouse skin treated with Acetone (Control), TPA, TPA+ATRA, and ATRA alone were probed with 
pB-Raf, pMek1/2, and pERK1/2 antibodies followed by an Alexa-546-labeled secondary antibody. Sections were counterstaining 
with DAPI. All panels were photographed at 600× magnification. B. Epidermal lysates were prepared in RIPA buffer from SEN-
CAR mouse skin treated with Acetone (Con), TPA, TPA+ATRA (T+A), or ATRA alone for 10 weeks. Total protein (15 μg per 
well) from pooled samples (n = 5) was run on 10% SDS-PAGE and probed with antibodies for total B-Raf, pB-Raf, total Mek1/
2, pMek1/2, total Erk1/2, pERK1/2, and β-actin. C. Epidermal thickness during the time course. Thickness was measured from 
digital micrographs of H&E stained skin sections as described in Methods. The symbols and error bars indicate the mean of 10 
measurements ± SEM.
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accompanying hyperproliferation. Fewer nuclei were
stained for TPA+ATRA treated skin than for TPA treatment
alone (Fig. 4A, bottom rows). We attempted to quantitate
pErk1/2 levels by determining the percent positive nuclei
in the treated skin. At all time points except 30 weeks, the
percent positive pErk staining nuclei actually decreased in
TPA treated skin compared to controls and TPA+ATRA
skin (data not shown). This was due to the far greater
number of total cells in the hyperplastic TPA treated skin.
To more precisely measure the levels of phosphorylation
of the MAP kinase signaling proteins in this model, we
performed Western blot analysis on epidermal lysates
pooled from 5 mice per treatment group for each time
point, from skin adjacent to the tissue that was embedded
for sectioning and IHC. Using 10 weeks as a representative
time point, co-administration of ATRA with TPA resulted
in a lower level of pB-Raf, pMek1/2 and pErk1/2, than
with TPA treatment alone (Fig. 4B compare TPA and
TPA+ATRA lanes). At the same time there is an increase in
the protein levels of total Erk1/2 with TPA treatment that
is suppressed by ATRA. The results from both IHC and
Western blot analysis indicate that suppression of pB-Raf,
pMek1/2, and pErk1/2 levels by ATRA.
P38 and JNK branches of the MAP Kinase cascade are not 
suppressed by ATRA treatment
The two other major MAP kinase signaling pathways
besides the B-Raf/Mek/Erk pathway are the Jun N-termi-
nal kinase (JNK) and p38 MAP kinase pathways. In order
to confirm our previous microarray results, which sug-
gested that these pathways were less important in regards
to ATRA suppression of TPA induced tumor promotion,
we performed IHC on tissue sections taken at the 7 week
time point from the same 2-stage skin carcinogenesis
experiment as above. Using antibodies to phosphorylated
(activated) p38 (Thr180/Tyr182), and JNK (Thr183/
Tyr185) we observed that, unlike the B-Raf, Mek1/2 and
Erk1/2 proteins, neither p38 nor JNK were increased in
phosphorylation upon TPA treatment (Fig. 5A, compare
TPA panels to Control). Importantly, the phosphorylation
levels of p38 and JNK were not suppressed by co-admin-
istration of ATRA with TPA (Fig. 5A, compare TPA and
TPA+ATRA panels). This observation was confirmed by
Western blotting using the same phospho-specific anti-
bodies, as well as antibodies to total p38 and total JNK
(Fig. 5B). Interestingly we observed a modest increase in
p38 phosphorylation in the skin treated with ATRA alone,
suggesting that the p38 pathway could play a role in medi-
ating retinoid effects in skin.
Sorafenib suppresses cell growth in TPA-induced tumors
We hypothesize that ATRA exerts its tumor suppressive
effect by blocking B-Raf/Mek/Erk signaling. This predicts
that blocking this pathway through another means should
also suppress tumorigenesis and/or the growth of tumors.
To test this prediction we have used a novel Raf inhibiting
bi-aryl urea compound from Bayer Pharmaceuticals called
BAY 43-9006, or Sorafenib [24]. This compound has been
shown to inhibit MAP kinase signaling in colon, pancre-
atic and breast cancer cell lines, as well as inhibit tumor
growth in colon, breast and non-small-cell lung cancer
mouse xenograft models.
Tumor-bearing SENCAR mice that had been treated topi-
cally with TPA, twice weekly for 27 weeks, were treated
with Sorafenib either topically or by gavage, as described
in the Materials and Methods. Mice were photographed
twice weekly to monitor tumor morphology and size.
Tumors that received only topical acetone solvent, along
with the TPA treatment, displayed the exophytic papil-
loma morphology normally observed in TPA-treated mice
in this model (Fig. 6A). The histological appearance of
these tumors was also typical of TPA-induced papillomas
(Fig. 6E). Tumors receiving topical Sorafenib at either con-
centration displayed a dried and darkened appearance
that was reminiscent of human keratoacanthoma (Fig. 6,
compare A to B and data not shown). Histological analy-
sis of these tumors revealed that the bulk of the tumor
mass was non-cellular keratin, indicating a greatly
enhanced level of squamous differentiation compared to
the control TPA-induced tumors (Fig. 6, compare E to F).
Interestingly, the tumors of mice treated with Sorafenib by
oral gavage did not differ drastically in outward appear-
ance from the control TPA-induced tumors. However
upon histological examination these tumors appear very
similar to the tumors that received topical Sorafenib (Fig.
6C and 6G). It was previously shown in the breast and
colon tumor xenograft models that inhibition of tumor
growth was closely associated with suppression of Erk1/2
phosphorylation [24]. We therefore stained paraffin-
embedded sections of the TPA-induced tumors, with and
without Sorafenib treatment, with the pErk1/2 antibody.
The number of nuclei and intensity of staining was
reduced for Sorafenib treated tumors compared to the
TPA only-treated tumors (Fig. 6H).
Discussion
ATRA is one of the most effective suppressors of tumor
formation in the 2-stage skin carcinogenesis model [8,9].
ATRA and other retinoids have also been studied exten-
sively for their potential as therapeutic and chemopreven-
tive agents for a variety of cancers, including skin cancer
[7,25-27]. However, in spite of the tremendous promise
for retinoids in therapy and prevention of cancer, clinical
results have often been disappointing due to hypervitami-
nosis A related side effects, leading to discontinuation of
treatment. Our group has attempted to understand the
chemopreventive mechanism of ATRA in order to moreMolecular Cancer 2009, 8:27 http://www.molecular-cancer.com/content/8/1/27
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TPA does not induce p38 and JNK phosphorylation Figure 5
TPA does not induce p38 and JNK phosphorylation. A. Paraffin sections of SENCAR mouse skin treated for 7 weeks 
with Acetone (Control), TPA, TPA+ATRA, and ATRA alone were probed with phospho-p38 and phospho-JNK antibodies fol-
lowed by an Alexa-546-labeled secondary antibody and DAPI counterstain. All panels in A were photographed at 600× magnifi-
cation. B. Western blots were run as in Fig. 4E for 7 week epidermal lysates and probed with antibodies for total p38, phospho-
p38 (p-p38), total JNK, phospho-JNK (p-JNK) and β-actin.
p-p38
p-JNK
Control ATRA TPA TPA+ATRA
p-p38
p-JNK
β-actin
Control
TPA
TPA+ATRA
ATRA
A
B
p38
JNKMolecular Cancer 2009, 8:27 http://www.molecular-cancer.com/content/8/1/27
Page 10 of 16
(page number not for citation purposes)
Figure 6 (see legend on next page)
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efficiently utilize these agents in the clinic, either alone or
in combination with other drugs.
In this study we have used microarray technology to iden-
tify genes responsible for the tumor suppressive effect of
ATRA. Specifically, we have used Affymetrix GeneChip®
Mouse Genome 430 2.0 arrays to probe mouse skin sub-
jected to the 2-stage chemical carcinogenesis protocol for
3 weeks, with and without co-administration of ATRA.
Among the TPA regulated genes identified, approximately
half were oppositely regulated, or counter-regulated, by
ATRA. We are calling these genes counter-regulated
because their direction of expression (increase or
decrease) in TPA + ATRA treated skin opposes that caused
by TPA treatment alone.
Clustering the counter-regulated genes into functional
categories has revealed that the MAP kinase signaling
pathway was the single most disproportionately repre-
sented. This of course does not exclude the potential
importance of other pathways that could mediate sup-
pression of tumor promotion by ATRA. However, because
elevated MAP kinase signaling has been implicated as one
of the key events for epidermal carcinogenesis and TPA
induced tumor formation [5,28-30], we chose to focus on
this pathway initially. While the control of expression of
genes in a particular signaling pathway and the control of
signaling through that pathway are not identical proc-
esses, several previous microarray analyses have demon-
strated a link between the two [31]. We also note that the
KEGG pathway term 'MAPK signaling pathway' that is
over-represented in our counter-regulated gene groups
includes genes that are upregulated downstream of the B-
Raf/Mek/Erk kinases (Table S1, additional file 2). We
therefore considered these microarray results to be a suit-
able guide for deciding which pathway(s) to analyze in
the context of this tumor model.
Since AP1 activity is stimulated by the MAP kinase path-
way [32], this implicates suppression of this pathway and/
or AP1 activity as the mechanism for the anti-tumor effect
of ATRA [18]. A number of different mechanisms have
been suggested, which include a RAR dependent exclusion
of Erk and CREB-binding protein from a promoter con-
taining AP1 binding sites [33], a restriction of nuclear
entry of activated Erk1/2 [34], a repression of Erk1 gene
expression at the level of transcription [35], an inhibition
of Erk1/2 kinase activity [36], and inhibition of epidermal
growth factor receptor (EGFR), a key upstream activator of
MAP kinase signaling [37]. Further evidence of the impor-
tance of this pathway as a target for ATRA in epithelial car-
cinogenesis comes from a recent study that showed that
ATRA could suppress proliferation of esophageal cancer
cells through activation of retinoic acid receptor β2 (RAR-
β2); and that this effect coincided with a suppression of
EGFR/Erk/AP1 signaling and suppression of cyclooxygen-
ase 2, a proinflammatory enzyme that is over-expressed in
several cancer types [38]. In this study we show for the first
time that in addition to blocking TPA regulation of expres-
sion of genes in the B-Raf/Mek/Erk pathway, ATRA also
blocks TPA-induced signaling through the pathway at
both early and late times during the 2-stage protocol.
The stress activated MAP kinase pathways (JNK and p38)
have often been observed to counteract malignant trans-
formation [39]. Consistent with those findings, we saw
that unlike for B-Raf/Mek/Erk proteins, TPA treatment did
not increase phosphorylation of either p38 or JNK. How-
ever ATRA treatment alone does enhance p38 phosphor-
ylation at Thr180/Tyr182 (Fig. 5A, ATRA panels, and 5B,
ATRA lane). This suggests that the tumor suppressive
activity of ATRA potentially involves activation of p38 sig-
naling. Further experiments are planned to explore this
possibility.
Interestingly, the ATRA resistant tumors were histologi-
cally distinct from TPA induced papillomas, closely
resembling advanced skin SCC (Fig. 3B). This is in agree-
ment with previous findings by other investigators who
showed that ATRA resistant tumors in the 2-stage model
were at higher risk for conversion to carcinomas [40].
Because the conversion rate of papillomas to carcinomas
is typically quite low, the numbers of mice used in our
study were not sufficient to statistically determine
whether TPA+ATRA papillomas had a higher conversion
rate to carcinomas than TPA papillomas. The ATRA resist-
Macroscopic appearance of papillomas from mice treated topically with TPA (1 μg/200 μl acetone, twice weekly) for 27 weeks,  followed by an additional 3 weeks of TPA treatment alone (A), 3 weeks of TPA co-administered with 0.3 μM Sorafenib applied  directly to the tumors (B) or TPA with 30 mg/kg Sorafenib administered by oral gavage (C) Figure 6 (see previous page)
Macroscopic appearance of papillomas from mice treated topically with TPA (1 μg/200 μl acetone, twice 
weekly) for 27 weeks, followed by an additional 3 weeks of TPA treatment alone (A), 3 weeks of TPA co-
administered with 0.3 μM Sorafenib applied directly to the tumors (B) or TPA with 30 mg/kg Sorafenib admin-
istered by oral gavage (C). H&E staining of 30 week TPA treated skin (D), papillomas treated with TPA alone (E), TPA + 
topical Sorafenib (F), and TPA + oral gavage administered Sorafenib (G). H. IHC staining of papillomas from mice treated topi-
cally with TPA for 27 weeks, followed by an additional 3 weeks of TPA treatment alone (left panel), 3 weeks of TPA co-admin-
istered with topical 0.3 μM Sorafenib (middle panel) or TPA with 30 mg/kg Sorafenib administered by oral gavage (right panel). 
Sections were probed with an anti-pErk1/2 antibody followed by an Alexa-546 labeled secondary antibody, and counterstained 
with DAPI. Sections were photographed at 600× magnification.Molecular Cancer 2009, 8:27 http://www.molecular-cancer.com/content/8/1/27
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ant tumors also expressed markedly lower levels of phos-
pho-B-Raf, -Mek1/2, and -Erk1/2 than the TPA papillomas
and TPA treated skin (data not shown), indicating that
activation of this pathway is not required for survival of
these tumors. We hypothesize that the ATRA resistance
may be due to circumvention of the B-Raf/Mek/Erk path-
way and that an alternate pro-proliferative pathway, such
as the Stat3 pathway, is involved in the development of
these tumors.
The mouse skin 2-stage model has been combined with
DNA microarray technology by several investigators to
more precisely define the gene expression changes related
to skin carcinogenesis. Of particular relevance to our study
is a report describing the gene expression profiles from
C57BL/6 mouse skin exposed to a single treatment with
TPA, using a cDNA microarray containing 5000 genes and
a subtracted hybridization technique [41]. These investi-
gators identified numerous previously unrecognized TPA-
regulated genes, as well as genes shown to be up-regulated
in advanced skin cancer. We note that several of these
genes were identified in 3 week TPA treated skin in our
study, in spite of the use of different mouse strains, micro-
array platforms and TPA treatment regimens. These
include the TPA upregulated genes JunB, Saa3 (serum
amyloid A3), Il4Rα (interleukin 4 receptor α), S100a9
(calgranulin B), Rrad (Ras-related associated with diabe-
tes), Krt2-6a (keratin complex 2, basic, gene 6a), and oth-
ers; as well as TPA downregulated genes such as Doc2γ
(double C2, gamma), Aebp1 (AE binding protein 1) and
others. In another study using the 2-stage model, investi-
gators identified genes whose expression was altered in
TPA treated skin, TPA-induced papillomas and SCCs,
compared to control skin [42]. These investigators further
determined by mRNA in situ hybridization that several of
these genes were similarly altered in human skin SCC
samples, indicating the relevance of the 2-stage model for
understanding human skin cancer. Some of these genes,
such as Lcn2 (lipcalin 2) and S100A8 (S100 calcium bind-
ing protein A8) were also upregulated in 3 week TPA
treated skin (data not shown). Other studies have been
conducted using microarrays to identify tumor associated
genes in human cell lines and tissue. One group has
directly compared genes differentially expressed between
normal cultured keratinocytes and skin SCC cell lines,
alongside a comparison of normal skin and skin SCC
samples [43]. Although there was little overlap between
the two systems, some of the tumor specific genes were
found in both SCC cell lines and tissue. In another study
using human samples, investigators compared the gene
expression profiles between normal skin, psoriatic skin
and skin SCC [44]. Some of the genes found to be com-
monly upregulated in psoriasis and skin SCC, such as
ADAM23, Krt16 (cytokeratin 16) and IVL (involucrin),
were also found to be upregulated in 3 week TPA treated
skin (data not shown). Psoriasis is a benign hyperplastic
disorder of the skin which bears some similarity to the
hyperplastic state of the 3 week TPA treated skin used in
our microarray study. However, there were also some
genes that were only upregulated in skin SCC, such as
EREG (epiregulin) and MMP13 (matrix metalloprotein-
ase 13), that were also upregulated in 3 week TPA treated
skin (data not shown). A cursory comparison of our data
to the above studies identifies few TPA-ATRA counter-reg-
ulated genes, but mainly genes upregulated by TPA with-
out alteration by ATRA. A more thorough comparison
between these studies and our findings for TPA treated
skin is planned. In the present study we have focused on
genes and pathways that are counter-regulated by TPA and
ATRA, rather than on the entire set of genes that are TPA
regulated.
There is often an inverse correlation between the degree of
squamous differentiation and malignancy in many can-
cers, including skin SCC. This observation has given rise
to the concept of differentiation therapy, whereby the nor-
mal differentiative state of tumor cells can be restored by
treatment with agents known to regulate differentiation
such as ATRA [45]. We observed that tumors treated with
Sorafenib, in addition to having suppressed Erk1/2 phos-
phorylation, have undergone extensive hyperkeratiniza-
tion (Fig. 6A and 6B). This suggests that Sorafenib could
potentially act as a tumor suppressor in skin SCC through
induction of squamous differentiation and the accompa-
nying exit from the cell cycle that results from blocking B-
Raf/Mek/Erk signaling. Future experiments will explore
the effects of Sorafenib in the 2-stage and UV induced skin
carcinogenesis models, and will compare them directly
with the effects of ATRA.
Conclusion
We have shown that approximately half of the TPA regu-
lated genes in mouse skin at an early pre-malignant stage
in the 2-stage protocol are oppositely affected when ATRA
is co-administered. These 'counter-regulated' genes pro-
vide the first expression signature for the chemopreventive
effect of ATRA in a mouse skin cancer model. This is a
potential source for novel targets for ATRA and other che-
mopreventive and therapeutic agents that can eventually
be tested in the clinic. In addition, ATRA targets the B-Raf/
Mek/Erk signaling pathway in the 2-stage model and this
activity coincides with its chemopreventive action. This
demonstrates the potential for targeting the B-Raf/Mek/
Erk pathway for chemoprevention and therapy of skin
SCC in humans. This is further supported by our finding
that a pharmacological inhibitor of B-Raf results in the
suppression of TPA-induced tumors.Molecular Cancer 2009, 8:27 http://www.molecular-cancer.com/content/8/1/27
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Methods
2-stage chemical carcinogenesis protocol
Young female outbred SENCAR mice were obtained from
the National Cancer Institute (Frederick, MD) and were
housed in a temperature- and humidity-controlled AAA-
LAC facility with a 12 h light/dark cycle. All procedures
were approved by the LSUHSC Institutional Animal Care
and Use Committee in accordance with NIH guidelines.
Mice were maintained on AIN-76A diet (Dyets, Bethle-
hem, PA), and allowed access to food and water ad libitum.
Mice were treated as follows. For the microarray screening
experiment, groups of 5 mice per treatment were shaved
on the dorsal side and two days later initiated with 2.56
μg (10 nMol) 7,12-dimethylbenz [a]anthracine (DMBA)
in 200 μl HPLC grade acetone, followed by twice weekly
applications of 1 μg (1.62 nmol) TPA in 200 μl acetone,
TPA plus 5 μg ATRA (16.67 nmol) in 200 μl acetone,
ATRA alone, or acetone solvent only for 3 weeks. For the
tumorigenesis and tissue analysis experiment, groups of
mice were treated as above, except that the TPA treatment
was carried out for 30 weeks. At the 3, 7 and 10 week time
points, groups of 5 mice for each treatment group were
sacrificed 6 hours after the last treatment, and the skin and
tumors harvested for protein and tissue isolation. Tumor
incidence (number of mice bearing tumors/total number
of mice in treatment group) and the tumor multiplicity
(average number of tumors per mouse) were recorded
weekly for an additional set of mice (n = 5/group) until
the 30 week time point. Tumor-bearing SENCAR mice
that had been treated topically with TPA, twice weekly for
27 weeks, were treated with Sorafenib as follows. One set
of mice were treated with the tosylate salt of Sorafenib
(BAY 54-9085) by oral gavage according to [24], with one
subgroup receiving 15 mg/kg and the other 30 mg/kg,
twice weekly. Sorafenib was administered immediately
following topical TPA treatment, which was continued
throughout the experiment. The other set of mice were
treated topically with Sorafenib, by direct application to
the tumors, twice weekly. One subgroup received 0.3 μM
Sorafenib in acetone solvent and the other received 0.6
μM. As for the gavage treatment, topical Sorafenib was
administered immediately following TPA application.
Tumor-bearing TPA treated mice were given topical ace-
tone solvent alone, also immediately following TPA treat-
ment, as controls. After three weeks of treatment with
Sorafenib and TPA, skin and tumor tissue was isolated
from all mice, 6 hours after the last set of treatments.
ATRA, DMBA, and TPA were obtained from Sigma (Sigma
Chemical Co., St. Louis, MO). Sorafenib (BAY 43-9006)
and it tosylate salt (BAY 54-9085) were generously sup-
plied by Bayer Pharmaceutical Division (West Haven,
CT).
Immunohistochemical examination of mouse skin and 
epidermal thickness
Dorsal skin from mice in the each of the treatment groups
was isolated and fixed in formalin and embedded in par-
affin prior to sectioning. Paraffin sections of 4 μm were
deparaffinized in xylene, 3 × 7 minutes, room tempera-
ture and rehydrated by stepwise washes in decreasing eth-
anol/H2O ratio (100% to 50%, followed by soaking in
water). Sections were cut and stained with hematoxylin
and eosin (H&E). For immunohistochemical staining,
sections were incubated in Superblock (Pierce Biotechnol-
ogy Inc., Rockford, Ill.) blocking reagent for 1 hour at
room temperature to block non-specific antigen sites.
After washing 3× in PBS, slides were incubated overnight
at 4°C with phospho-specific antibodies against B-Raf
(Ser 445), Mek1/2 (Ser 217/221), Erk1/2 (Thr202/
Tyr204), SAPK/JNK (Thr183/Tyr185), p38 MAPK
(Thr180/Tyr182) (Cell Signaling Technologies Inc.), and
cytokeratin 10 (DAKO). Slides were photographed on a
Nikon TE300 fluorescence microscope under oil immer-
sion, at 600× magnification, with a CCD camera (Roper
Scientific). Images were processed with IPLabs v3.55 soft-
ware (Scanalytics Inc.). Epidermal thickness was meas-
ured using digital images of H&E stained skin sections,
photographed at 400× magnification. Ten randomly
selected fields were measured for each data point, using
the rectangular marquee tool in Photoshop to determine
the number of vertical pixels from the bottom of the basal
cell layer to the beginning of, but not including, the stra-
tum corneum. The length of each pixel was determined to
be 0.169 μM, using a digital image of a hemocytometer
grid, also photographed at 400×, for calibration.
Skin RNA isolation
Total cell RNA was isolated by homogenization of snap
frozen skin in TriReagent (Molecular Research Center Inc.,
Cincinnatti, OH), followed by standard organic extraction
and precipitation and purification on RNeasy RNA purifi-
cation columns (Qiagen Inc., Valencia, CA). Purity and
yield were determined using an Agilent 2100 Bioanalyzer
(Agilent Technologies).
RNA labeling and GeneChip hybridization
Fluorescent probe synthesis and array hybridization was
performed in the LSUHSC-S DNA Array Research Core
Facility laboratory using established methods provided by
Affymetrix (Affymetrix Inc., Santa Clara, CA). Briefly, 2 μg
of purified total cell RNA, pooled from 3–5 mice in each
treatment group, was reverse transcribed into cDNA, using
a T7 promoter-(dT)24 primer. Following second strand
synthesis, biotin-labeled cRNA was generated from the
double stranded template using T7 polymerase. The qual-
ity of the cRNA probe was verified by running an aliquot
on an agarose gel. Exactly 20 μg of the labeled cRNA was
hybridized to the Affymetrix GeneChip® Mouse GenomeMolecular Cancer 2009, 8:27 http://www.molecular-cancer.com/content/8/1/27
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430 2.0 Array for 16 hours at 45°C in 300 μl of pre-mixed
hybridization solution containing labeled hybridization
control prokaryotic genes (bioB, bioC, bioD, and cre).
Several duplicate spots for each control gene are present
on the chip. Chips were washed in the GeneChip Fluidics
Station automatic washer and scanned on the GeneArray®
fluorometric scanner.
DNA microarray analysis and visualization
Data extraction and examination of the raw intensity data
was conducted within the LSUHSC-S DNA Array Core
Facility using MicroArray Suite 5.0 (Affymetrix Inc.) and
the freeware software package dChip (from Dr. Wing
Wong's laboratory, http://biosun1.harvard.edu/complab/
dchip/). Gene expression data sets were further analyzed
using GeneSifter (VizX Labs, Seattle, WA) and NetAffx
(Affymetrix Inc.) microarray analysis software packages in
addition to proprietary algorithms and tools developed at
LSU-Shreveport. Differential expression and subsequent
visualization of genes counter-regulated by TPA and ATRA
was performed based on the fold change between three
pairs: the signal intensity value of the TPA-treated skin
(TPA) with skin treated with acetone solvent alone (con-
trol), TPA+ATRA treated skin with TPA, and between
TPA+ATRA and control. Scatterplots were drawn for each
of these three sets of comparisons (Fig. S1, additional file
1). Each scatterplot represents a gene as a single dot, with
unchanged genes appearing on the diagonal where the
log-transformed x and y values are equal or very similar.
Linear boundaries parallel to the x = y diagonal line repre-
sent the 2-fold and 4-fold borderlines. We considered
only genes for which the p value ≤ 0.05 for signals within
a probe set for a given gene, and for which there was a
present call for either control, TPA treated skin, or both.
We first identified the genes regulated by TPA treatment
relative to untreated controls and divided these into 2
clusters, C1 (increased in expression ≥ 1.5-fold by TPA
treatment) and C2 (decreased in expression ≥ 1.5-fold by
TPA treatment). The C1 group was further divided into
three subclusters; C1sA are genes suppressed by ≥ 1.5-fold
upon TPA+ATRA co-administration compared to TPA
alone; C1B are genes that remain relatively unchanged
upon co-administration of TPA+ATRA relative to TPA
alone, and C1C are genes that are further induced by ≥
1.5-fold by TPA+ATRA relative to TPA alone. The C2 clus-
ter was also divided into three subclusters. C2A are genes
induced by ≥ 1.5-fold upon TPA+ATRA co-administration
compared to TPA alone; C2B are genes that remain rela-
tively unchanged upon co-administration of TPA+ATRA
relative to TPA alone, and C2C are genes that are further
suppressed by ≥ 1.5-fold by TPA+ATRA relative to TPA
alone. The expression patterns for each of these groups are
shown in the graphs in Fig. 2, alongside the correspond-
ing heatmap. For this figure, we normalized each gene to
a mean of 0 and a standard deviation of 1, and utilized
sorting based on the similarity of each gene's three meas-
urements (control, TPA and TPA+ATRA). To obtain the
heatmap representation, each gene expression value is
represented graphically by coloring a cell in the table on
the basis of the measured fluorescence ratio. Unchanged
genes are colored black, while up-regulated genes are
shown in red and down-regulated genes in green.
The complete microarray datasets for control, TPA-, ATRA-
, and TPA+ATRA-treated samples have been entered into
the LSU Health Science Center MicroArray Database,
which is MIAME compliant and administered by the Lab-
oratory for Advanced Bioinformatics at the Department of
Computer Sciences at LSU-Shreveport.
Western blotting
Mouse epidermis was scraped from isolated dorsal skin
on ice and homogenized with a Polytron for three 10 sec
bursts in RIPA lysis buffer (150 mM NaCl, 50 mM Tris-
HCl pH 7.5, 1 mM EDTA, 1% NP-40, 1 mM PMSF, 1 mM
Na-orthovanadate) supplemented with 40 μl Complete
protease inhibitor cocktail (Roche, Indianapolis, IN)
according to manufacturer-provided instructions.
Extracted protein was quantified using the Bio-Rad Pro-
tein Assay kit (Hercules, CA). Proteins were separated by
SDS acrylamide gel electrophoresis (12%) and transferred
to nitrocellulose membranes (Schleicher & Schuell, Das-
sel, Germany). Blots were blocked with 5% BSA for 1 h at
room temperature, followed by incubation overnight
with antibodies against phosphorylated forms of B-Raf
(Ser 445), Mek1/2 (Ser 217/221), Erk1/2 (Thr202/
Tyr204), SAPK/JNK (Thr183/Tyr185), and p38 MAPK
(Thr180/Tyr182); and total B-Raf, c-Raf, Mek1/2, Erk1/2,
p39 and SAPK/JNK; and human β-actin (all from Cell Sig-
naling Technology, except for B-Raf and β-actin from
Santa Cruz Biotechnology). Blots were washed with TBS/
0.1% Tween 20 and incubated with horseradish peroxi-
dase-conjugated secondary antibody for 1 h at room tem-
perature, followed by 3 additional washes with TBS/0.1%
Tween 20. Chemiluminescence detection was performed
according to the manufacturer's instructions (Pierce,
Rockford, Ill.), followed by exposure to X-ray film.
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